Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)

被引:13
|
作者
Mata, Guillaume [1 ]
Miles, Dillon H. [1 ]
Drew, Samuel L. [1 ]
Fournier, Jeremy [1 ]
Lawson, Kenneth, V [1 ]
Mailyan, Artur K. [1 ]
Sharif, Ehesan U. [1 ]
Yan, Xuelei [1 ]
Beatty, Joel W. [1 ]
Banuelos, Jesus [1 ]
Chen, Jie [1 ]
Ginn, Elaine [1 ]
Chen, Ada [1 ]
Gerrick, Kimberline Y. [1 ]
Pham, Amber T. [1 ]
Wong, Kent [1 ]
Soni, Divyank [1 ]
Dhanota, Puja [1 ]
Shaqfeh, Stefan G. [1 ]
Meleza, Cesar [1 ]
Narasappa, Nell [1 ]
Singh, Hema [1 ]
Zhao, Xiaoning [1 ]
Jin, Lixia [1 ]
Schindler, Ulrike [1 ]
Walters, Matthew J. [1 ]
Young, Stephen W. [1 ]
Walker, Nigel P. [1 ]
Leleti, Manmohan Reddy [1 ]
Powers, Jay P. [1 ]
Jeffrey, Jenna L. [1 ]
机构
[1] Arcus Biosci Inc, Hayward, CA 94545 USA
关键词
QUANTITATIVE ASSESSMENT; PI3K INHIBITORS; LIPOPHILICITY; PERMEABILITY; INFLAMMATION; DISCOVERY;
D O I
10.1021/acs.jmedchem.1c01153
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Phosphoinositide-3-kinase gamma (PI3K gamma) is highly expressed in immune cells and promotes the production and migration of inflammatory mediators. The inhibition of PI3K. has been shown to repolarize the tumor immune microenvironment to a more inflammatory phenotype, thereby controlling immune suppression in cancer. Herein, we report the structure-based optimization of an early lead series of pyrazolopyrimidine isoindolinones, which culminated in the discovery of highly potent and isoform-selective PI3K gamma inhibitors with favorable drug-like properties. X-ray cocrystal structure analysis, molecular docking studies, and detailed structure- activity relationship investigations resulted in the identification of the optimal amide and isoindolinone substituents to achieve a desirable combination of potency, selectivity, and metabolic stability. Preliminary in vitro studies indicate that inhibition of PI3K gamma with compound 56 results in a significant immune response by increasing pro-inflammatory cytokine gene expression in M1 macrophages.
引用
收藏
页码:1418 / 1444
页数:27
相关论文
共 50 条
  • [21] Impact of PI3K (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis
    Laurent, Pierre-Alexandre
    Hechler, Beatrice
    Solinhac, Romain
    Ragab, Ashraf
    Cabou, Cendrine
    Anquetil, Typhaine
    Severin, Sonia
    Denis, Cecile V.
    Mangin, Pierre H.
    Vanhaesebroeck, Bart
    Payrastre, Bernard
    Gratacap, Marie-Pierre
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (09) : 2041 - 2053
  • [22] Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K)
    Mishra, RK
    Scaife, JE
    Harb, Z
    Gray, BC
    Djukanovic, R
    Dent, G
    ALLERGY, 2005, 60 (09) : 1204 - 1207
  • [23] Assessing the role of phosphoinositide 3-kinase (PI3K) in head and neck cancers
    Shen, W.
    El Dinali, M.
    Braegelmann, J.
    Zoergiebel, J.
    Kundu, A.
    El-Hashani, E.
    Salgia, R.
    Seiwert, T.
    EJC SUPPLEMENTS, 2010, 8 (07): : 66 - 66
  • [24] Towards understanding phosphoinositide 3-kinase γ (PI3Kγ)-dependent signaling network
    Zagar, Andreja Vujicic
    Scapozza, Leonardo
    Vadas, Oscar
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2015, 71 : S239 - S239
  • [25] Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
    Spoerke, Jill M.
    O'Brien, Carol
    Huw, Ling
    Koeppen, Hartmut
    Fridlyand, Jane
    Brachmann, Rainer K.
    Haverty, Peter M.
    Pandita, Ajay
    Mohan, Sankar
    Sampath, Deepak
    Friedman, Lori S.
    Ross, Leanne
    Hampton, Garret M.
    Amler, Lukas C.
    Shames, David S.
    Lackner, Mark R.
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6771 - 6783
  • [26] Structure-Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability
    Stec, Markian M.
    Andrews, Kristin L.
    Booker, Shon K.
    Caenepeel, Sean
    Freeman, Daniel J.
    Jiang, Jian
    Liao, Hongyu
    McCarter, John
    Mullady, Erin L.
    Miguel, Tisha San
    Subramanian, Raju
    Tamayo, Nuria
    Wang, Ling
    Yang, Kevin
    Zalameda, Leeanne P.
    Zhang, Nancy
    Hughes, Paul E.
    Norman, Mark H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (14) : 5174 - 5184
  • [27] Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors
    Al Hasan, Mohammad
    Sabirianov, Matthew
    Redwine, Grace
    Goettsch, Kaitlin
    Yang, Stephen X.
    Zhong, Haizhen A.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 121
  • [28] A bibliometric analysis of highly cited Phosphoinositide 3-Kinase (PI3K) research papers
    Ho, Yuh-Shan
    Hartley, James
    COLLNET JOURNAL OF SCIENTOMETRICS AND INFORMATION MANAGEMENT, 2020, 14 (01) : 37 - 54
  • [29] Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability
    Kawada, Hatsuo
    Ebiike, Hirosato
    Tsukazaki, Masao
    Yamamoto, Shun
    Koyama, Kohei
    Nakamura, Mitsuaki
    Morikami, Kenji
    Yoshinari, Kiyoshi
    Yoshida, Miyuki
    Ogawa, Kotaro
    Shinma, Nobuo
    Tsukuda, Takuo
    Ohwada, Jun
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (24) : 7650 - 7660
  • [30] Elucidation of the mechanism of phosphoinositide 3-kinase (PI3K) inhibitor mediated dyserythropoiesis in rodents
    Ledieu, D.
    Bunn, I.
    Rosner, E.
    Wuersch, K.
    Hopfer, U.
    TOXICOLOGY LETTERS, 2015, 238 (02) : S282 - S283